Peptide Atlas · Cofactor

NADH (Nicotinamide adenine dinucleotide, reduced)

In a randomized, double-blind crossover pilot study in 26 people with chronic fatigue syndrome, 8 responded to a stabilized oral form of NADH (the reduced form of nicotinamide adenine dinucleotide) against 2 on placebo.

emerging

provisional
PubChem 439153
2 citations
0 discussions
0 followers
Coenzyme I reduced
DPNH
beta-NADH
dihydronicotinamide adenine dinucleotide
reduced NAD

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

Evidence, kept apart

The Atlas never mixes evidence types into one blob. Each claim below carries the tier it actually sits in; an unresolved citation is shown and does not move the page.

Evidence map for NADH (Nicotinamide adenine dinucleotide, reduced). Tier reflects study design, not enthusiasm.
Claim	Tier	Source
Oral NADH in chronic fatigue syndrome: 8/26 responders versus 2/26 on placebo (pilot crossover RCT)	emerging	pmid 10071523
Oral NADH is degraded before it can supply nicotinamide in mice	preclinical	pmid 16802695

Unanswered questions

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.